Glialogix Overview
- Founded
-
2008
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Glialogix General Information
Description
Operator of biotechnology firm intended to develop therapeutics for neurodegenerative disease. The company's product is an improved proprietary formulation of an existing FDA-approved drug and is being developed for the treatment of progressive multiple sclerosis, enabling patients to have access to a drug that slows the progression of chronic neurodegenerative diseases.
Contact Information
Website
www.glialogix.com
Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 38 Bayo Vista Avenue
- Larkspur, CA 94939
- United States
Glialogix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 18-Jul-2022 | Completed | Out of Business | |||
| 2. Accelerator/Incubator | 01-Jan-2013 | Completed | Startup | |||
| 1. Grant | 11-Feb-2012 | $268K | Completed | Startup |
Glialogix Patents
Glialogix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200009118-A1 | Compositions and methods for the treatmentof neurodegenerative and other diseases | Inactive | 21-Oct-2016 | 00000000000 | |
| US-20180110760-A1 | Compositions and methods for the treatmentof neurodegenerative and other diseases | Inactive | 21-Oct-2016 | 00000000000 | |
| AU-2014212109-B2 | Compositions and methods for the treatment of neurodegenerative and other diseases | Inactive | 01-Feb-2013 | 0000000000 | |
| AU-2018222921-A1 | Compositions and methods for the treatment of neurodegenerative and other diseases | Inactive | 01-Feb-2013 | 0000000000 | |
| US-9918997-B2 | Compositions and methods for the treatment of neurodegenerative and other diseases | Inactive | 01-Feb-2013 | A61K31/635 |